http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017044619-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ff81a650b70e913d3b2524b45e4c7320 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01J49-0036 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-68 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate | 2016-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4bcb7f49fe94ee660ea76b95f912b39d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7eea6071131667e053ced3f40210aed1 |
| publicationDate | 2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2017044619-A1 |
| titleOfInvention | Profiling chemically modified dna/rna units for disease and cancer diagnosis |
| abstract | The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MS n ), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020212512-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10651024-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3725895-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10049868-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019139752-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018158665-A1 |
| priorityDate | 2015-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 899.